Edvard Abel
Impact in
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Cells and Metastasis
Papers in
-
- Head and Neck Cancer Studies 6
-
- Advanced Radiotherapy Techniques 2
- Co-authors
- Jan Nyman (7 shared papers)Thomas Björk‐Eriksson (5 shared papers)Eva B. Hammerlid (4 shared papers)Ewa M. Silander (3 shared papers)Hedda Haugen Cange (3 shared papers)Karin Söderkvist (2 shared papers)Lalle Hammarstedt‐Nordenvall (2 shared papers)Per Gunnar Nilsson (2 shared papers)
- Journals
- Acta Oncologica (4 papers)Advances in Radiation Oncology (3 papers)International Journal of Radiation Oncology*Biology*Physics (2 papers)Acta Oto-Laryngologica (1 paper)Lung Cancer (1 paper)
- Partner nations
- SwedenNorwayUnited States
In The Last Decade
Edvard Abel
15 papers receiving 2.8k citations
Edvard Abel's Hit Papers
Peers
Comparison fields: 5 of 77
- Otorhinolaryngology 1.4k
- Oncology 1.3k
- Cancer Research 78
- Immunology 103
- Pulmonary and Respiratory Medicine 144
Countries citing papers authored by Edvard Abel
This map shows the geographic impact of Edvard Abel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edvard Abel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edvard Abel more than expected).
Fields of papers citing papers by Edvard Abel
This network shows the impact of papers produced by Edvard Abel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edvard Abel. The network helps show where Edvard Abel may publish in the future.
Co-authors
The 25 scholars most cited alongside Edvard Abel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2497 |
| 2 | 2020 | 127 | |
| 3 | 2017 | 30 | |
| 4 | 2019 | 29 | |
| 5 | 2012 | 22 | |
| 6 | 2017 | 22 | |
| 7 | 2014 | 20 | |
| 8 | 2024 | 16 | |
| 9 | 2022 | 13 | |
| 10 | 2005 | 10 | |
| 11 | 2019 | 5 | |
| 12 | 2022 | 2 | |
| 13 | 2025 | 2 | |
| 14 | 2025 | 1 | |
| 15 | 2026 | 1 |
About Edvard Abel
Edvard Abel is a scholar working on Otorhinolaryngology, Radiation, Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 15 papers that have together received 2.8k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (6 papers), Lung Cancer Treatments and Mutations (2 papers), Cancer Genomics and Diagnostics (2 papers), Brain Metastases and Treatment (2 papers), Advanced Radiotherapy Techniques (2 papers), Chemotherapy-induced organ toxicity mitigation (1 paper), Cancer Immunotherapy and Biomarkers (1 paper) and Gastrointestinal motility and disorders (1 paper). The work is most often cited by research in Otorhinolaryngology (1.4k citations), Oncology (1.3k citations), Cancer Research (78 citations), Immunology (103 citations) and Pulmonary and Respiratory Medicine (144 citations). Edvard Abel has collaborated with scholars based in Sweden, Norway and United States. Frequent co-authors include Jan Nyman, Thomas Björk‐Eriksson, Eva B. Hammerlid, Ewa M. Silander, Hedda Haugen Cange, Karin Söderkvist, Lalle Hammarstedt‐Nordenvall, Per Gunnar Nilsson, Eva Brun and Johan Reizenstein. Their work appears in journals such as Acta Oncologica, Advances in Radiation Oncology, International Journal of Radiation Oncology*Biology*Physics, Acta Oto-Laryngologica and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.